Background. Multipeptide vaccines for melanoma may cause inflammatory adverse events (IAE). We hypothesize that IAE are associated with a higher rate of immune response (IR) to vaccination and improved clinical outcomes. Methods. Adult patients with resected, high-risk (stage IIB to IV) melanoma were vaccinated with a combination of 12 class I major histocompatibility complex (MHC)-restricted melanoma epitopes, and IAE were recorded. A separate category for hypopigmentation (vitiligo) was also assessed. CD8
ABSTRACT
Background. Multipeptide vaccines for melanoma may cause inflammatory adverse events (IAE). We hypothesize that IAE are associated with a higher rate of immune response (IR) to vaccination and improved clinical outcomes. Methods. Adult patients with resected, high-risk (stage IIB to IV) melanoma were vaccinated with a combination of 12 class I major histocompatibility complex (MHC)-restricted melanoma epitopes, and IAE were recorded. A separate category for hypopigmentation (vitiligo) was also assessed. CD8
? T cell IR was assessed by direct interferon gamma ELISpot analysis. Overall survival and disease-free survival were analyzed by Cox proportional hazard modeling. Results. Out of 332 patients, 57 developed IAE, the majority of which were dermatologic (minimum Common Terminology Criteria for Adverse Events [CTCAE] grade 3). Most nondermatologic IAE were CTCAE grade 1 and 2. Vitiligo developed in 23 patients (7 %). A total of 174 patients (53 %) developed a CD8
? response. Presence of IAE was significantly associated with development of IR (70 vs. 49 %, p = 0.005) and with disease-free survival (hazard ratio 0.54, p = 0.043). There were no significant associations relating vitiligo or IR alone with clinical outcomes. Conclusions. IAE are associated with a higher rate of CD8
? T cell response after vaccination therapy for highrisk melanoma. Our findings suggest either that antitumor activity induced by class I MHC-restricted peptide vaccines may depend on immunologic effects beyond simple expansion of CD8
? T cells or that the intrinsic inflammatory response of patients contributes to clinical outcome in melanoma.
Immune therapies can induce durable clinical benefit in patients with advanced melanoma, but autoimmune toxicities can limit their use and have been lethal in some patients. 1 Cancer vaccines may induce protective antitumor immunity in high-risk patients and augment this clinical benefit by combination with other effective immune therapies. Melanoma vaccines can elicit cellular immune responses (IR) from CD8
? cytotoxic T cells and CD4
?
helper T cells, and may induce clinical responses alone or in combination. [2] [3] [4] Toxicities with vaccine therapies are rare but can include local or systemic inflammatory responses, including ulcerations, dyspnea, and autoimmune toxicities. 5, 6 Although evidence exists linking delayed-type hypersensitivity after vaccination with the induction of a cellular IR, there is a paucity of research assessing the relationship between vaccine toxicity and clinical effect in melanoma immunotherapy. 7, 8 We have previously reported IR patterns and clinical outcomes of vaccination with a combination of 12 class I major histocompatibility complex (MHC)-restricted peptides administered with Montanide ISA-51 adjuvant among patients with resected stage IIB to IV melanoma. inflammatory adverse events (IAE) did occur for some patients. 11, 13 Although it is tempting to attribute these events to a cellular IR, no conclusive data exist to support this. There is, however, evidence to suggest that hypopigmentation (vitiligo) after melanoma immunotherapy may be a predictor of clinical response. 14, 15 The purpose of the present study was to test the hypothesis that IAE and vitiligo are associated with CD8
? T cell response and clinical outcomes after vaccine immunotherapy for resected, highrisk melanoma.
METHODS
This study included patients with stage IIB to IV highrisk resected melanoma receiving a vaccine composed of 12 class I MHC-restricted melanoma peptides (12MP) in one of three prospective phase 2 clinical trials. All patients had complete ELISpot results. Clinical trial design and assay protocols are reported in detail elsewhere. [9] [10] [11] [12] [13] In brief, all three trials assess the CD8
? T lymphocyte response to 12MP, administered in Montanide ISA-51 with or without granulocyte-macrophage colony-stimulating factor (GM-CSF) or cyclophosphamide (Table 1) . For all trials, T cell response was assessed through peripheral blood mononuclear cell sampling using ELISpot analysis with the following definitions of results: N vax = number of T cells responding to vaccine peptide; N neg = number of T cells responding to maximum negative control; and R vax = N vax /N neg . An IR to the 12MP vaccine was present if all of the following conditions were met: (1) N vax -N neg C20 cells/100,000 CD8
? T cells, (2) R vax C2, (3) (N vax -1 SD) C (N neg ? 1 SD), and (4) R vax after vaccination C2 9 R vax before vaccination.
After vaccination, patients underwent scheduled followup over a maximum of 10 years based on previously described protocols. Follow-up sessions assessed melanoma progression and adverse events, which were reported as treatment-related toxicities. IAE categories are defined in Table 2 , and severity criteria were based on the common terminology criteria for adverse events (CTCAE), version 3.0. For each event, date of symptom onset was recorded; when this was not available, date of follow-up with first toxicity documentation was used as a proxy for date of onset.
STATISTICAL ANALYSIS
We compared the rate of IR between patients who developed IAE and patients who did not by a chi-square test of association. Summary statistics were used to describe the chronologic relationship between IAE and IR, Hypopigmentation analyzed separately as a noninflammatory dermatologic adverse event comparing the date of IAE onset to the date of peripheral blood sampling that yielded the first evidence of CD8
? T lymphocyte response.
Kaplan-Meier survival estimates, log rank test, and Cox proportional hazard models (PROC PHREG in SAS 9.2; SAS Institute, Cary, NC) were used to perform landmark time-to-event analyses of overall survival (OS) and disease-free survival (DFS). Landmark analysis focused on IAE and IR that occurred within 8 weeks of initiating the vaccination protocol. OS was calculated as the time elapsed from the 8-week postregistration date to either death or loss to follow-up, while DFS was calculated as the time elapsed from the 8-week postregistration date to death, recurrence/progression of disease, or loss to followup. The following baseline characteristics were included in the models: stage (II vs. III vs. IV), IAE (yes/no), IR (yes/ no), age, and gender. Stage was based on patient status at study entry. Patients experiencing the outcome of interest (OS or DFS) before the 8-week window were excluded from landmark analysis. For this reason, 1 and 14 individuals were excluded from the analysis of OS and DFS, respectively. Assumptions of the Cox proportional hazard models were assessed using graphical methods. A twosided Type I error rate of 0.05 was used.
The present study was conducted under the sanction of the institutional review board of the University of Virginia (HIC 10524, 11491, and 13498).
RESULTS
A total of 332 patients met the inclusion criteria for the present study. Median age was 56 years, and 31.3 % (104 of 332) of patients were women. Forty-four patients were enrolled with disease stage IIB/IIC, 45 with stage IIIA, 182 with stage IIIB/IIIC, and 61 with stage IV. Median followup time was 5.4 years. Across all trials, 52.7 % (174 of 330) of patients produced a CD8
? T cell response by ELISpot criteria, 17.2 % (57 of 332) developed an IAE, and 6.9 % (23 of 332) developed vitiligo. Of patients who developed IAE, 41 presented with dermatologic, 19 with constitutional, and 9 with pulmonary symptoms (Supplementary Table 1 ). Patients with nodular melanoma growth patterns were more likely to develop an IAE than patients with the superficial spreading pattern (31.1 % vs. 10.7 %, p = 0.012). IAE rate was lower in the in the vaccine composed of 6 class II MHC-restricted melanoma helper peptides (6MHP) arms of Mel44 compared to the other trial protocol arms (p = 0.008, Table 1 ). Within Mel43, the rate of IAE among patients who received GM-CSF was 23 % (14 of 60), compared to 36 % (22 of 61) among those who did not (p = 0.16). Within Mel44, patients who received cyclophosphamide had an IAE rate of 8 % (7 of 84), compared to 7 % (6 of 83) among those who did not (p = 1.0). One patient belonged to two vaccine trials; this patient did not develop an IAE within either trial, and only data from this patient's initial study were used in analysis.
Overall, patients who were IAE positive had a higher rate of IR (odds ratio [OR] 2.36, p = 0.005, Table 3 ). Under subgroup analysis, this significant association held true for Mel43 (OR 2.75, p = 0.017) and Mel44 (OR 3.90, p = 0.033). Under subgroup analysis by IAE type, only dermatologic IAE were associated with a significantly increased rate of CD8
? T cell response (OR 2.75, p = 0.005). These dermatologic IAE were principally local vaccine-site reactions. Conversely, among patients who developed an IR, rate of IAE occurrence was twice that of patients who did not have an IR (22 vs. 12 %, p = 0.005, not shown). Temporally, IAE tended to occur after the onset of IR, with a median delay of 1.0 (interquartile range 0.4 to 2.3), 0.2 (interquartile range -0.1 to 0.4), and 0.8 (interquartile range 0.4-1.1) months for dermatologic, constitutional, and pulmonary subtypes, respectively (Supplemental Fig. 1 ). Because vitiligo was considered to represent an autoimmune response, the timing relationship between peripheral IR and vitiligo onset was not calculated; however, median onset of vitiligo was at 9 monthsconsiderably delayed after IR positivity.
Associations of IAE, IR, and vitiligo with OS and DFS, as assessed via Kaplan-Meier estimation, are presented in Fig. 1 . There was no significant association of OS with IR, IAE, or vitiligo. Although IR and vitiligo also were not associated with DFS, IAE was significantly associated with improved DFS (log rank p = 0.024). However, with only 7 % of patients experiencing vitiligo, our ability to detect significant associations with this variable was low. Assessing univariate relationships by symptom subgroups, patients experiencing dermatologic IAE trended toward improved DFS; however, this relationship did not reach statistical significance (p = 0.096). Constitutional and pulmonary symptom subgroups were too small for independent analysis. Results from the proportional hazard models indicated only younger age and male gender were associated with improved OS, while only the presence of IAE was associated with improved DFS (hazard ratio 0.54, Wald p = 0.043, Table 4 ).
DISCUSSION
As treatment protocols for high-risk melanoma continue to evolve, the balance between clinical benefit and dosedependent toxicity is continuously scrutinized. Therapies that provide the highest overall response rates are at times limited to treatment for refractory cases or adjusted to less efficacious doses due to risks of serious organ injury. 1, [16] [17] [18] Our results highlight an alternative viewpoint of adverse events, suggesting that an association is present between IAE and cellular IR after administration of a combination class I MHC-restricted peptide vaccine. This relationship is most evident for dermatologic IAE. Moreover, there exists an association between these adverse events and DFS that is not explained entirely by the development of peripheral CD8
? T lymphocyte responses, and IAE confer a stronger prediction of clinical outcome after vaccination than does the presence of a CD8
? T lymphocyte response. The benefit toward DFS among IAE-positive patients after immunotherapy appears to be conferred during the initial 2 years, which argues for consideration of more intensive monitoring among patients who do not develop an early ? T lymphocyte proliferation has not been an area of intensive research. Our findings point to the potential presence of a group of intrinsically hyperresponsive patients for whom antitumor vaccine therapy may be particularly efficacious. The concept of intrinsic hyper response is evident in the association between local dermatologic reactions and TH2 response among children vaccinated with DTaP. 8 Although we did not assess for CD4 T lymphocyte proliferation in response to melanoma antigens across this study, our results are in line with findings that effector T cell proliferation follows onset of rash among patients experiencing herpes zoster reactivation. 19 A potential relationship between delayed-type hypersensitivity (DTH) and peripheral T cell response after vaccination has been explored in cancer immunotherapy. Our finding of an association between dermatologic IAE and peripheral IR suggests that peripheral CD8
? T cells may be trafficking to vaccine sites and contributing to DTH and dermal inflammation. 10, 20 This mechanism is supported by other studies associating DTH and T cell proliferation after administration of vaccines derived from HER-2/neu and colon cancer cells. 21, 22 Vaccine-induced effector-memory CD8
? T lymphocyte proliferation has been shown to predict immunotherapy efficacy against tumors. [23] [24] [25] By demonstrating improved DFS associated with IAE but not IR, we allude to mechanisms of antitumor activity through 12MP vaccination beyond induction of a CD8
? cytotoxic lymphocyte response. Local and systemic adverse events after vaccination are most commonly attributed to proinflammatory cytokine release by macrophages, T lymphocytes, and other cells. Within our series, IAE were most commonly either constitutional or dermatologic. Mediators of flulike syndromes are typically attributed to acute-phase reactants such as tumor necrosis factor alpha (TNF-a), which has cellular-level effects of macrophage activation, neutrophil migration, and cell-death signaling. TNF-a surge has been noted after smallpox vaccination, correlating with constitutional symptoms. 26, 27 Within the dermis, TNF-a is stored in mast cells and is released in response to immune stimulus, resulting in erythema, induration, and pain typical of dermatologic IAE within our series. 28 Our finding that IAE after vaccination are associated with DFS suggests a potential connection with antitumor effects of TNF-a in melanoma. 29, 30 Other cytokines up-regulated after vaccination include interferon gamma (IFN-c), interleukin (IL)-2, and IL-4, each offering additional mechanisms for antitumor activity independent of CD8 ? T lymphocyte proliferation. 31 IFN-c promotes cellular immunity via T-H1 lymphocyte differentiation and increased MHC class I expression on antigenpresenting cells. Although IL-4 has down-regulatory effects on T-H1 differentiation and IFN-c expression, its induction of an IgE response via plasma cell differentiation may contribute to durable clinical responses given IgE's applications as a passive immunotherapeutic in solid tumors. 32, 33 Finally, treatment of advanced-stage melanoma with IL-2 alone or in combination with other immunotherapeutic agents has been ongoing, with durable clinical benefit in a small subset of patients.
15,34-38
Although we did not find a significant relationship between hypopigmentation and clinical outcomes, there was an early divergence between survival curves for patients with vitiligo and patients without (Fig. 1) . With only 23 cases of vitiligo captured, our study volume may be underpowered to detect this relationship. Bystryn et al. 14 first reported significantly better 5-year survival among melanoma patients who developed vitiligo. Furthermore, patients with melanoma who develop vitiligo also show an improved rate of objective response to immunotherapy with IL-2. 15 Our findings are in concordance with these data, and they prompt further exploration with a larger patient sample.
The present study has several limitations. Because each vaccine contains several components, we are not able to identify which component is responsible for each IAE. GM-CSF and cyclophosphamide may promote IAE through dendritic cell activation and regulatory T cell inhibition, respectively. Interestingly, within Mel43, patients who were treated with GM-CSF actually trended toward fewer IAE (23 %) than those who were not (36 %) . This is consistent with our prior report that among vaccinated patients, T cell responses were negatively associated with GM-CSF. Similarly, there was no significant effect of cyclophosphamide on IAE, which is consistent with the lack of effect on measured T cell responses. 11, 13 Vaccine regimens also differed in whether they included helper peptides, and for reasons that are unclear, there was a lower incidence of IAE with administration of 6MHP in Mel44. Host factors-such as melanoma growth pattern-may also contribute to adverse events for reasons that are not clear. Overall, however, we believe that patient groups were large enough to dilute these variations, and there were no significant differences in DFS or OS when comparing the three trials by univariate analysis. Moreover, analyzing the clinical outcomes of intrinsic hyper response is valid regardless of the inciting agent that exposed this characteristic. The relationship between IAE and nodular growth pattern is somewhat surprising, as nodular melanomas tend to have worse prognosis and higher local recurrence rates. 39 Statistical modeling was performed using time-toevent analysis with a landmark adjustment. Repeating analyses without the landmark adjustment did not change the association between IAE and DFS. Although timedependent analysis is more common, it would have accounted for events occurring years after vaccination, which are less likely to be truly vaccine related. Last, despite being the largest study of its kind, our patient volume was insufficient to generate conclusions regarding the proliferative response implications of pulmonary IAE.
In conclusion, IAE after vaccination with the combination 12MP class I MHC-restricted melanoma vaccine are associated with a higher rate of CD8
? T cell response and better DFS among patients with high-risk melanoma. Their prognostic utility may be harnessed to influence monitoring protocols during the first 2 years after treatment. Interestingly, the positive association between DFS and IAE does not appear to be directly related to CD8
? T cell response. It may involve unanticipated effects of vaccine components, possibly including effects of one or more vaccine-induced cytokines.
